Ablynx NV (XBRU:ABLXS) Total Liabilities : €209.99 Mil (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Total Liabilities?

Ablynx NV's Total Liabilities for the quarter that ended in Dec. 2017 was €209.99 Mil.

Ablynx NV's quarterly Total Liabilities declined from Dec. 2016 (€163.71 Mil) to Jun. 2017 (€154.81 Mil) but then increased from Jun. 2017 (€154.81 Mil) to Dec. 2017 (€209.99 Mil).

Ablynx NV's annual Total Liabilities declined from Dec. 2015 (€237.36 Mil) to Dec. 2016 (€163.71 Mil) but then increased from Dec. 2016 (€163.71 Mil) to Dec. 2017 (€209.99 Mil).

Ablynx NV Total Liabilities Historical Data

The historical data trend for Ablynx NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Total Liabilities Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Liabilities

Get a 7-Day Free Trial

167.39

147.87

237.36

163.71

209.99

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Total Liabilities	Get a 7-Day Free Trial															237.36	189.74	163.71	154.81	209.99

Ablynx NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ablynx NV's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	89.442	+	(88.715	+	21.044
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.791	+	0)
	=	209.99

Total Liabilities	=	Total Assets (A: Dec. 2017 )	-	Total Equity (A: Dec. 2017 )
	=	389.848	-	179.856
	=	209.99

Ablynx NV's Total Liabilities for the quarter that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	89.442	+	(88.715	+	21.044
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.791	+	0)
	=	209.99

Total Liabilities	=	Total Assets (Q: Dec. 2017 )	-	Total Equity (Q: Dec. 2017 )
	=	389.848	-	179.856
	=	209.99

Ablynx NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines